

A year in review

BII IMPACT REPORT 2021

Bringing ideas to life
and research to market

Bringing ideas to life
and research to market

BII

BioInnovation
Institute

2021 was a breakthrough
for BII start-ups attracting extra
funding for new solutions to many
of society's major challenges

BII

- — **Dec. 2021**
Start-ups at BII have raised more than DKK 1 billion
- — **Dec. 2020**
BII becomes an independent foundation
- — **Feb. 2019**
Professor Jens Nielsen appointed as CEO
- — **Nov. 2018**
BII grand opening Nørrebro, Copenhagen
- — **Sep. 2018**
BII opens the first calls
- — **Jan. 2018**
BII initiated a three-year establishment phase

Welcome

2021 was our first year as a commercial foundation with a non-profit objective.

During the year, BII has launched many new initiatives to make an impact for people and society, and the many start-up companies in BII's community within life science and biotechnology are growing at a fast pace.

BII has awarded grants and loans to high-growth start-up companies at a total of more than DKK 400 million (EUR 56.3 million), and the companies have in 2021 already raised more than DKK 1 billion (EUR 145.5 million) in external funding.

The life science innovation ecosystem is thriving and has never been stronger, as stated in the recent report about the Danish Life Science Ecosystem. At the same time, there is an urgent need for solutions to many of the significant societal challenges. There is therefore still

much to be done, and it is only through entrepreneurship that science is translated to commercially sustainable and successful solutions benefitting people and society.

To push for that development, we have broadened our outreach to attract the very best ideas and strengthened our programs to create the best learning environment. As a result, the BII brand is getting stronger and we experience more applications from other Nordic and European countries.

At BII, we celebrate the power of working together, also with external partners, collaborators and service providers. Partnerships and collaborations continue to be crucial components in the continued development and success of BII, and we are therefore thrilled that we can present two joint initiatives: one with the Bill & Melinda Gates Foundation on raising awareness

of the women's health agenda internationally; and one with the scientific journal Science to support the BII innovation agenda in the form of an international science innovation prize.

I hope you will enjoy our 2021 Impact Report that will describe highlights and provide information about some of our programs and companies.

Jens Nielsen
Chief Executive Officer
BioInnovation Institute





BII

BioInnovation
Institute

38%
Increase in applications for
our programs 2020–2021

58
Start-ups supported
2018–2021

27
Projects and start-ups
supported in 2021

~EUR
56.3 million
awarded in grants and loans
2018–2021

~EUR
145.5 million
funding raised by start-ups
2018–2021

173
Jobs in BII start-ups
2021

SoMe and digital communications

+13,000 followers on social media
+3,000 recipients of BII's monthly newsletter



This report is based on BII active programs 2021. It includes eight convertible loans for start-ups from the Venture Lab program that were conditionally approved in 2021 and thereafter finally approved.

Looking back at 2021

Together with the executive management, engaged BII staff members run the various programs and support development projects. BII staff help to increase the value of start-up projects and facilitate the journey from research to commercialisation for the project- and start-up teams in BII's programs.

"In 2021, BII took its impact-focused research efforts to the next level by establishing the new Bio Studio program with the ambition of creating a leading translational facility in Europe, and through our unique joint initiative with the Bill & Melinda Gates Foundation to drive research and innovation within women's health."

— **Trine Bartholdy**
CIO, Chief Innovation Officer, BII



"2021 has been an exciting year for me, focusing on optimising our board process. Furthermore, I took part in arranging and hosting the first BII Summer School, which was a rewarding experience, as the participants seemed to have a great and meaningful week."

— **Marie Vedel**
PA to CEO, BII



BII BioInnovation
Institute

BII

Vision

BII's vision is to support world-class life science innovation that drives development of new solutions by early life science start-ups for the benefit of people and society.

Mission

BII's mission is to incubate world-class life science and catalyse its commercialisation of new solutions through start-ups by using our knowledge, network, funding and infrastructure.



"Despite the overarching challenge of Covid-19, we managed to gather and strengthen our community through new innovative solutions. It has been great to see how everyone has been keen on adapting to a different reality quickly."

— **Tina Chanruk Larsen**
Communication and Community
Building Specialist, BII

"In 2021 BII has witnessed a substantial supply of health tech innovations in the ecosystem, and we look forward to supporting the translation of these innovations into products that bring benefits to people and society."



— **Tony Cheng-fu Chang**
Senior Business Developer, BII



Introducing BII's three focal points

What BII is looking for are projects that are built on excellent science as it enables the start-up to pivot and find potential markets as its project advances.

Our three strategic focus areas support this journey: A refined program structure that fits the individual needs, the nurturing of the portfolio to attract further investment and grow the business, and finally the outreach and collaborative involvement of strategic key players.



Expanding our catalyst platform

BII has tested, evaluated and shaped the programs to meet the needs from early acceleration to maturation towards Series A investment.

Besides BII Venture Lab and BII Creation House, BII has set up BII Residence and transformed BII Faculty into Bio Studio to foster the start-ups of tomorrow.

Supporting our thriving portfolio

BII funding, business development support, lab and office infrastructure and global network have allowed our portfolio to thrive. The portfolio today is strong within every field and continues to attract larger investments including Series A. The portfolio also provides solutions to societal changes on topics like women's health and sustainable food production.

By the end of 2021, we reached a milestone when the companies incubated at BII reached around EUR 145 million in total financing. Start-ups that have raised additional funding have in total raised 4.8 times the amount we have supported the companies with, which clearly shows the value generated when we support early-stage life science start-ups in bringing their research to market.

Outreach, community & collaborations

We build partnerships and collaborations with corporates and companies, universities and hospitals, investors and experts. This year we have added substantial collaborations with Bill & Melinda Gates Foundation, with the objective of strenghtening the ecosystem with women's health, and the scientific journal Science.

Small, large, national and international collaborations and partnerships all support the creation of a strong foundation and community for the years to come.




Expanding our
catalyst platform

Our four programs


“The Venture Lab program has a “never too early” mentality and focuses on helping founders become start-up leaders. It isn’t easy, and we are thankful for the trust our founders place in us while on that journey.”

— **Christian Brix Tillegren**
Program Manager, Venture Lab, BII



“To accomodate more mature companies, we have set up a BII Residence Program where eight start-ups have relocated to BII to become a part of our entrepreneurial environment and to expand their global network.”

— **Bo Heinemann**
Laboratory Manager, BII



Through **Bio Studio**, we assist researchers in building companies in strategically important areas that address some of the grand societal challenges.

The **Venture Lab** program assists very early-stage start-ups with interesting technology but an unclear path to the market.

In our **Creation House** program, start-ups with validated technology, well-defined IP and a clear path to market can build an attractive case for Series A investors.

The **Residence** program is for life science companies that have raised VC funding or other forms of financing. The residents rent space on market terms and have access to offices, labs and fully functional labs, as well as business development assistance or entrepreneurship training.

Funding



Grant of
-EUR 3.2 million

Convertible loan of
-EUR 500,000

Convertible loan of
-EUR 1.3 million

No funding
from BII

Purpose



Establish start-ups
based on transformative
technologies

Venture Lab is designed to
help newly established start-
ups in the early phases

Maturation of projects
to attract substantial
funding

Residence offers an
entrepreneurial
environment to well-
established start-ups

Key outcome



New viable
start-ups

Scientific development,
business development
and team development

A prototype or
lead candidate

A large global
network in the
ecosystem

Duration



Up to three
years

12
months

Up to 18
months

Up to 24
months



Expanding our
catalyst platform

BII's entrepreneurial environment is
shaped and nurtured every day by our
employees, start-up teams and everyone
who joins us in bringing research to market.

We strive to work by three core values.
We call them the BII Basics.

Impactful

Catalytic

Passionate




BioInnovation
Institute



Expanding our catalyst platform

More international applications

World-class science is found across the globe. Where BII in 2020 experienced an increase in the number of Nordic applications, 2021 showed an increase in especially European applications indicating that BII has become more widely known.



16

European countries submitted applications to BII in 2021

Entrepreneurs from 16 European countries submitted applications to BII in 2021. 43% came from outside Denmark, which is a 20% increase from 2020.



In 2021, 27 projects and start-ups were supported.

27 projects and start-ups



The start-up Stimuliver, a new company from Edinburgh in Scotland developing liver implants, is one of the BII start-ups moving to Denmark.

Watch Stimulivers Taking the Leap video here:



3 focus Areas

28%
Health Tech



28%
Bioindustrials



44%
Therapeutics



BII covers all three verticals in life sciences, from therapeutics, to health tech solutions, to the bioindustrial space.

The bioindustrials share has grown from 14% of the portfolio in 2020 to 28% of the projects and start-ups awarded in 2021.

This demonstrates significant growth due to green transformation, novel foods and plant-based foods with new ingredients.



Expanding our catalyst platform

New projects and start-ups in 2021

In 2021, 27 new projects/start-ups, including two stand-alone grants received BII grants and loans totaling EUR 22.2 million. From 2020 to 2021 there was a 38% increase in applications. Total amount awarded 2018–2021: EUR 56.3 million.

First time entrepreneurs in BII start-ups in 2021

74%




“We see an increase in deal flow to BII, including more applications from other European countries, which shows we are fulfilling an important role in translating science to product.”

— Maria Henriques De Jesus
Business Developer, BII

95%
increase in **projects and start-ups**
from 2020–2021

38%
increase in **applications**
from 2020–2021



Bio Studio

EUR
6.6 million
Granted amount

6
projects

Note: The 6 projects have been granted as part of the Faculty program preceding the Bio Studio program.



BII Venture Lab

EUR
9.5 million
Granted amount

145
Applications

15
start-ups

10%
Approval rate



BII Creation House

EUR
5.5 million
Granted amount

32
Applications

4
start-ups/
grants and
loans

13%
Approval rate

Stand-alone
grants

EUR
0.6 million
Granted amount

2
projects

BII's history wall

August Krogh
Physiologist
(1874 – 1949)




In 1920, August Krogh was awarded the Nobel Prize for his outstanding scientific research that resulted in the discovery of the capillary motor regulating mechanism.



1920

In 1922, August Krogh introduced insulin production in Denmark. This saved his own wife's life as well as numerous other lives.


August Krogh's insulin production led to the foundation of Terapeutisk Laboratorium Novo.




1925

novo nordisk fonden
1951

In 2017, The Novo Nordisk Foundation awarded EUR 53 million over three years to establish BII.



2018



BII
BioInnovation
Institute

It is often a winding road to success for an entrepreneur. At BII, the start-ups receive help to take the first steps to embark on an entrepreneurial journey filled with ups and downs.

In the fall of 2018, BII cut the ribbon to its new offices and lab facilities after months of intensive work.

Right from the beginning, life science entrepreneurs flocked to BII, resulting in much more applicants than available spots in its programs.

Just two years later, BII was spun out as an independent foundation with long-term financing from the Novo Nordisk Foundation of up to EUR 470 million over 10 years.

When start-ups leave BII, their research-based innovations continue to make an impact for the benefit of people and society.



Marie Krogh
Physiologist
Married to August Krogh
(1874 – 1943)

H.C. Olesen
Physician
(1888 – 1971)

August Krogh
Pharmacist
(1870 – 1939)



Expanding our
catalyst platform

Educating the next generation of bioentrepreneurs

Education for bioentrepreneurs is of high importance to BII. Education not only helps to raise and develop abilities and competences, but also to support decision making in a truly interdisciplinary context of research and business.



“There is one common challenge among start-ups and that is dealing with failure. Teams that succeed in constructively dealing with failure perform much better than others. Failure will occur over and over again, and successful teams handle this.”

— Cecillie Willer

Executive Coach, MSc Psychology & Business
and responsible for the Halo programme



Crunches

The crunches are monthly events during the Venture Lab program where the start-ups dive into a specific topic relating to company building, for the purpose of strengthening business acceleration throughout the program.

In each crunch the start-ups learn new vocabulary, are introduced to new tools and inspiring international speakers and work on case studies. At the end of each crunch, the start-ups generate an actionable component in their business plan.



Halos

Halos form a holistic tailored program that enables researchers to grow and cope with the special challenges they face personally and interpersonally when building a business.

A Halo consists of a smaller group of founders that connect and receive support using a combination of tools and resources from the executive coaching world.

Halos constitute a meaningful community to share frustrations, celebrate the small victories, and gather strength to overcome the hard moments, with inspiration from the other founders and guidance from executive coach, Cecillie Willer.


Summer school

BioInnovation Institute and CBS Executive hold an annual summer school to raise awareness among 40 European post-docs and young researchers on how to take great science from the lab to the first investment round.

The students get an overview of key aspects of commercialisation and planning of innovative projects within bioindustrials, health tech and therapeutics.

The program offers teaching in the form of lectures from CBS Executive, hands-on experience from industry presenters and BII's Business Development team as well as pitch training and advice from highly skilled venture capitalists from BII's network.








Supporting our
thriving portfolio

Additional funding

Since 2018, 38 companies have raised EUR 145.5 million in capital either through investments or soft funding from various granting agencies in the EU and Denmark.


- Danish grants
EUR 7.9 million
- Danish investments
EUR 43 million
- Foreign grants
EUR 10 million
- Foreign investments
EUR 65.6 million



EUR
12.7 million

5 start-ups

2021:
EUR 8.7 million



EUR
6.3 million

7 start-ups

2021:
EUR 2.6 million



EUR
126.5 million

26 start-ups

2021:
EUR 88 million

Additional funding raised by BII's start-ups

from 2018 to 2021 in accumulated values

38 BII start-ups have managed to raise 4.8 times the amount they were awarded by BII in additional funding. This achievement demonstrates that the relatively small amount of capital, in combination with the network, infrastructure, knowledge, and help provided by BII, attract further investments to these businesses and accelerate their growth.

EUR
145.5 million

raised by BII start-ups
2018–2021



4.8x

Additional funding added
to the BII funding



Supporting our
thriving portfolio

Some success stories from 2021

Success stories from 2021 can be hard to pick, because there were plenty. The following examples highlight some of the successes in terms of attracted funding, awards and exposure in high-impact journals.



Orbit Health raised **EUR 1 million** in additional funding from MTE

Read more about
Orbit Health
using this QR code:



Sundew raised **EUR 1.4 million** in funding and acquired MicroSynbiotix (MSX) and its algal RNA-platform

Read more about
Sundew
using this QR code:



Adcendo raised **EUR 51 million** in Series A financing

Read more about
Adcendo
using this QR code:



Cirql Biomedical received 'Index Award 2021' and was featured in WIRED UK

Read more about
Cirql Biomedical
using this QR code:



Chromologics raised **EUR 6 million** in seed round financing

Read more about
Chromologics
using this QR code:



Synklino raised **EUR 14 million** from Eir Ventures, Vækstfonden and 70 private investors

Read more about
Synklino
using this QR code:



Pephexia Therapeutics ApS raised **EUR 403,000** from Vækstfonden

Read more about
Pephexia Therapeutics
using this QR code:



EvodiaBio was featured in Nature Biotechnology / Nature Portfolio

Read more about
EvodiaBio
using this QR code:




173 Employees
in BII start-ups in 2021

Read more success
stories using this
QR code:





Adcendo develops treatment of soft-tissue sarcoma (STS), a cancer type occurring in many places in the body.



Supporting our thriving portfolio

Adcendo raises EUR 51 million in series A financing

Adcendo develops a novel cancer treatment for a number of cancer indications with the strongest focus on soft-tissue sarcoma (STS), a cancer type occurring in many places in the body. Additional cancer types in scope include glioblastomas, which are found in the brain, and osteosarcoma, which are bone cancers.

“BioInnovation Institute has positioned us and helped us get in front of the right investors. The network surrounding us here has helped our case, and we will be staying until we are ready to establish ourselves on our own”, says CEO Henrik Stage.

Even though the founders behind Adcendo are first-time entrepreneurs, they raised EUR 51 million in Series A financing in 2021, led by Novo Seeds and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. With this size of investment, says Henrik Stage, we will be able to run things in parallel in the next few years and that is a huge advantage.

Adcendo is a spinout from The Finsen Laboratory, The University of Copenhagen and Rigshospitalet.




BI BioInnovation Institute



A photograph of four people (three men and one woman) standing in a modern office hallway. From left to right: a man in a dark blue polo shirt, a woman in a light grey blazer over a white top, a man in a grey polo shirt and glasses, and a man in a green long-sleeved shirt. They are all looking towards the camera.

**ComMIT Biologics
develops a new type of
immunotherapy for the
treatment of cancer.**



Supporting our
thriving portfolio

BII gave a clear direction to our company

When ComMIT Biologics entered BII's Venture Lab program in September 2021, they only knew that they had great scientific data that could potentially benefit cancer patients at a later stage.

"We thought about our start-up as someone offering a platform technology in the oncology space, but we had a hard time defining our focus and how we could make an impact", says Nick Stub Laursen, CEO of ComMIT Biologics.

But through BII's network, the start-up was exposed to a wide range of investors and by pitching repeatedly, it has become clearer over time which direction it should take to gain traction among investors.

"As a scientific founder team you learn to understand the importance of a pitch deck with a clear story that people can understand", says Mikael Winkler, CSO and Co-founder of ComMIT Biologics.

Breakthrough in London

As an incubated company at BII, ComMIT Biologics was also invited to the prestigious BioSeed conference in London. And after a couple of months with valuable learnings from constant investor dialogue, the pitch that the company gave in the English capital turned out to be a game-changer.

"We would never have ended up on a stage pitching for so many excellent and high-profile investors if it wasn't for BII who sponsored our participation. The event has really paid dividends, since the majority of the investors we are speaking with currently were present on that conference", emphasises Mikael Winkler, CSO of ComMIT Biologics.


And it is exactly those investors that the ComMIT Biologics team devotes most of their time on now. A process that is going well as they have developed rapidly and do not make those rookie mistakes that can be costly for an early-stage start-up.

"Science is still going to be the foundation of the company's success, but as an entrepreneur, you need to adapt to a different way of thinking. That's something you learn relatively fast when you transition from academia to being part of BII", concludes Nick Stub Larsen, CEO of ComMIT Biologics.

"When you come from academia you are used to thinking that data speaks for itself, but when you present your start-up to investors your mindset needs to be completely different."

— Mikael Winkler
CSO and Co-founder of ComMIT Biologics.






Supporting our thriving portfolio

Bioindustrials at BII

Bioindustrial innovation is one of the most promising areas of developing technology. It opens the way to sustainable, scalable and innovative solutions, meets grand challenges and has the potential to solve major global crises. At BII, the companies Sundew and EvodiaBio work with food and beverages in a sustainable perspective.

BII BioInnovation Institute



BII BioInnovation Institute



EvodiaBio

EvodiaBio is a company driven by sustainability and with a clear mission to produce flavoursome non-alcoholic beer without harming the environment through colossal water consumption, fertilizers to grow the hops, and a big carbon footprint transporting goods around the globe. Currently, it takes 3,000 liters of water per kilo of hops and requires a large amount of landmass to produce the aromas for non-alcoholic beers.

Historically, it has been tough to make aroma compounds using biological methods because they are composed of structurally complex volatile molecules that are hard to produce and harvest. However, after several years of research at the University of Copenhagen, the founders of EvodiaBio had a breakthrough. As a part of BII's Venture Lab program, they work to get a minimum viable product for at least eight different standard aroma blends.

The bioindustrial innovation is one of the most promising areas of developing technology for societal impact

BII BioInnovation Institute



BII BioInnovation Institute

BII BioInnovation Institute




BII BioInnovation Institute

Sundew

Aquaculture is the world's fastest-growing food sector, with an estimated USD 250 billion (FAO 2020) in annual revenues. Still, farmers face a major challenge managing parasites and diseases, with finfish stock losses in excess of USD 9.6 billion per year. Many of the current products used to control pests and diseases are environmentally damaging chemicals such as formaldehyde, copper and salt. Thus, Sundew endeavors to provide new effective, selective and environmentally benign alternatives to make fish farming more sustainable.

Sundew is already developing its first product, Biokos, an extract from a naturally occurring microbe, which is highly efficient at killing the important protozoan parasite 'ich'. By the end of 2021, the company further accelerated its commercialisation efforts by acquiring the Irish biotech company MicroSynbiotix and through EUR 1.4 million in funding from the Yield Lab Europe and the Danish Growth Fund.



Supporting our
thriving portfolio

“BII offers fully equipped co-working laboratory space that enables companies to work actively in the laboratory from day one of their stay.


The laboratory space is divided into common co-working areas, and various specialised labs, and we have now opened for 1,100m² of GMO Class 1 and 40m² of GMO Class 2 general lab space and no less than 15 specialised labs. Despite the COVID situation the laboratories are buzzing with activity from 21 projects and start-ups.”



— Bo Heinemann
Laboratory Manager, BII



BioInnovation
Institute



Supporting our
thriving portfolio

BII & Investors



"BII start-ups routinely pitch to our VC network to obtain feedback. This is key to their success, and we are passionate about helping founders understand and implement it for future success."

— Bobby Soni
Chief Business Officer, BII



In 2021 BII start-ups
delivered more than
100 pitches for
the investor team



BII offers a stage to all companies
to meet **30+ investors**

BII invites investors
to join the BII pitch
calendar

Investors select
companies for
pitch

BII hosts the
virtual pitch
session

BII facilitates
follow-up
meetings

ABINGWORTH
Life Science Investing

Sofinnova
partners

SR One

NOVO
holdings


BioVentures
MedTech Funds

red alpine

wellingtonpartners

T H E
MARCH
FUND


SOUND
BIOVENTURES




Outreach, community
& collaborations

BII and the ecosystem

In 2021, our community of collaboration partners has increased. We have built close collaborations with key players and important institutes nationally and internationally who have trusted us with their expertise and research. It is through a collective effort that we can bring ideas to life and research to market.





Outreach, community
& collaborations

New partnerships

BII has put more focus into international collaborations and partnerships. In 2021 this has resulted in two major collaborations with Bill & Melinda Gates Foundation and the scientific journal Science.

“The BII team’s capabilities and strong commitment to Women’s Health has impressed us. We are excited to have BII as a strategic partner to complement our efforts in catalysing innovation, with the goal of improving the health of women and girls, especially in low-income countries —bringing us closer to a more gender-equal world.”

— Katrine Thor Andersen

Deputy Director, Global Health, Bill & Melinda Gates Foundation

Strategic partnership with Bill & Melinda Gates Foundation

BII has entered into a strategic partnership with Bill & Melinda Gates Foundation, strengthening the ecosystem with women's health from research to viable company creation and to identify new technologies and solutions that can improve the health of women and girls across the world, including low-income countries.

As part of the partnership, BII has received a grant to map and identify leading research and start-up opportunities for women's health, undertake community building and start up awareness creating activities with key stakeholders. In parallel, eligible research projects will be subject to funding considerations by BII.

BILL & MELINDA
GATES foundation



Read more about
Bill & Melinda Gates Foundation
using this QR code:



Read more about
BII & Science Prize for Innovation
using this QR code:



“BII launched the BII & Science Prize for Innovation in collaboration with AAAS/ Science magazine. Through the prize, we want to reward and honor the work of early-career scientists with exceptional potential of translating their research into novel life-changing solutions for the benefit of people and society.”



— Jens Nielsen
Chief Executive Officer
BioInnovation Institute

BII | Prize for
Science | Innovation



New innovation prize

Behind every life-changing solution is an entrepreneurial scientist - a creative mind who proved an idea in the lab and dared to carry it out in the world.


In partnership with one of the world’s top academic journals, Science, BII announced a new annual innovation prize in 2021.

The “BII & Science Prize for Innovation” seeks to recognise bold researchers asking fundamental questions at the intersection of life sciences and entrepreneurship.

The prize will be awarded to scientists who can show that they have reached across field boundaries with an enthusiasm that combines outstanding basic science with an eye toward application in the marketplace.

Bill Moran, Publisher, Science family of journals: “BII is an organisation that is passionate about nurturing early career researchers and providing them with the tools and knowledge to move their discoveries to the next stage. BII provides expert guidance that allows scientists to become innovators in research. This is the reason why we are proud of our prize collaboration with BII.”


The prize will be awarded the first time in 2022, and winners will receive a cash prize (USD 25,000 for the winner; USD 10,000 for the two runners-up).



Outreach, community
& collaborations

Outreach and community

In 2021, the BII community has been very active in its outreach activities. Due to the pandemic it has been managed as live, hybrid and online events. More than 200 activities have been reported, among them 84 talks and presentations and 55 workshops. BII has also managed to establish social media profiles that now exceeds 13,000 followers.



Webinars

Webinars attracted more than 500 participants in 2021 and presented a variety of subjects spanning from program presentations to thematic topics like venture capital's view on (e)valuation in life science and healthcare to more individual presentations like INKEF Capital, a venture capital firm based in Amsterdam, backing promising early-stage companies in Europe.

1.17K

Pieces of coverage

3.75K

Social shares

28

Countries, reach of coverage



SoMe & digital
communications

13K

Followers on social media

3K

Recipients of BII's
monthly newsletter

+200

Activities in 2021



Events

BII has an open door policy and seeks to share inspiration, engagement, insights and entrepreneurship among students to pursue a research and entrepreneurial career. At Medical Innovation Day 2021, BII brought together around 75 students, researchers and entrepreneurs to exchange ideas and think up solutions for health challenges of the future. As part of the open door policy BII welcomed 20 lab technician students from Aarhus Business Academy to visit the BII laboratories.




The Square

Talks at "The Square" are very popular among the BII start-ups and projects and draw a lot of attention. Despite the limited opportunities for physical events in 2021, it was possible to set up three talks featuring Francesco Gatto (co-founder of Elypta), Eran Segal (Weizmann Institute), Anja Boisen (Health Technology, Technical University of Denmark) together with Robert Burger (BlueSense Diagnostics).



Talks and presentations

BII and start-ups have delivered 84 talks and presentations during 2021, covering conferences, symposia and workshops all over the world. Some were live, some hybrid and some online. The talks include 13 keynotes, e.g. at King's College in London, Institute Pasteur in Paris, and highly esteemed conferences and workshops like the International Metabolic Engineering conference and workshop in Healthcare and Life Science & Entrepreneurship.



Outreach, community
& collaborations

Meet the start-ups

BII strives to become a leading powerhouse in northern Europe for start-up mature projects in life science. An important element in succeeding is to create an attractive atmosphere for both first-time and serial entrepreneurs.

"Our idea is to provide new microbial solutions to reduce microbial resistance and pollution and to make food production more sustainable."

"At BII Venture Lab we expect to get valuable help and many business insights and become more certain about our value proposition. At the same time, we feel that we can benefit from BII's community and receive advice from other companies on journeys similar to ours."

— CEO, Morten Østergaard Andersen
Bloomix



"HEI Therapeutics endeavors to solve the long-standing challenge in healthcare where there is simply a lack of insight for chronic disease patients to manage their conditions in between follow-up visits better."

"Through developing an at-home monitoring solutions platform, the company is paving the way for better-personalised management and treatment of chronic conditions for millions of patients worldwide, starting with thyroid-related conditions."

"In BII Venture Lab we will focus on finalising the technology and device prototype to initiate pre-clinical trials in hospital settings with key collaboration partners."

— Founders, Winnie E. Svendsen and Jesper Kimer
HEI Therapeutics

"Pephexia Therapeutics is a biotechnology company working on innovative treatment of cachexia causing unintended weight loss plus at least three other criteria such as anorexia, decreased muscle strength and abnormal biochemistry."

"Becoming a part of Creation House helps us financially, and it is also a seal of approval to become a part of BII. Furthermore, there is a great environment where you work alongside other entrepreneurs working with life science. Lastly, it is also nice to have a good office space, laboratory space and access to good meeting rooms. It increases professionalism and is a big step forward for us."

— CEO, Keld Fosgerau
Pephexia



BII start-ups and alumni

Examples of start-ups we have had the privilege to work with since 2018.





Bringing ideas to life
and research to market

Passion, professionalism, support, facilities,
funding, programs, collaborations and networks.

BII BioInnovation
Institute

BioInnovation Institute Foundation
Ole Maaløes vej 3, 3rd floor
DK-2200 Copenhagen N
Denmark

E info@bii.dk
W bii.dk

Produced by the Novo Nordisk Foundation
Impact Department and BioInnovation Institute.

©2022 BioInnovation Institute Foundation
All rights reserved
ISBN 978-87-973974-0-4

An international life
science institute.
We are here to help
you bring your
research to market.



BioInnovation Institute Foundation

Ole Maaløes vej 3, 3rd floor
DK 2200 Copenhagen N
Denmark

E info@bii.dk
W bii.dk

ISBN 978-87-973974-0-4